TW200640451A - Use of estrogen receptor-β selective agonists for radiation- or chemotherapy-induced mucositis and radiation cystitis - Google Patents

Use of estrogen receptor-β selective agonists for radiation- or chemotherapy-induced mucositis and radiation cystitis

Info

Publication number: TW200640451A
Authority: TW; Taiwan
Prior art keywords: radiation; chemotherapy; estrogen receptor; cystitis; selective agonists
Prior art date: 2005-02-16

Application number

TW095104866A

Other languages

English (en)

Inventor

William Jacobson

Heather A Harris

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-16

Filing date

2006-02-14

Publication date

2006-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36597596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200640451(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-14 Application filed by Wyeth Corp filed Critical Wyeth Corp

2006-12-01 Publication of TW200640451A publication Critical patent/TW200640451A/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Dermatology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

TW095104866A 2005-02-16 2006-02-14 Use of estrogen receptor-β selective agonists for radiation- or chemotherapy-induced mucositis and radiation cystitis TW200640451A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US65337605P	2005-02-16	2005-02-16

Publications (1)

Publication Number	Publication Date
TW200640451A true TW200640451A (en)	2006-12-01

Family

ID=36597596

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095104866A TW200640451A (en)	2005-02-16	2006-02-14	Use of estrogen receptor-β selective agonists for radiation- or chemotherapy-induced mucositis and radiation cystitis

Country Status (20)

Country	Link
US (1)	US20060211672A1 (zh)
EP (1)	EP1848427A1 (zh)
JP (1)	JP2008530210A (zh)
KR (1)	KR20070103456A (zh)
CN (1)	CN101119721A (zh)
AR (1)	AR053332A1 (zh)
AU (1)	AU2006214515A1 (zh)
BR (1)	BRPI0608154A2 (zh)
CA (1)	CA2596984A1 (zh)
CR (1)	CR9263A (zh)
GT (1)	GT200600064A (zh)
IL (1)	IL185009A0 (zh)
MX (1)	MX2007009914A (zh)
NI (1)	NI200700182A (zh)
NO (1)	NO20073901L (zh)
PE (1)	PE20061092A1 (zh)
RU (1)	RU2007128819A (zh)
TW (1)	TW200640451A (zh)
WO (1)	WO2006088784A1 (zh)
ZA (1)	ZA200706785B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20071043A1 (es) *	2006-02-14	2007-10-23	Wyeth Corp	FORMULACIONES FARMACEUTICAS ACUOSAS QUE COMPRENDE LIGANDOS SELECTIVOS DEL RECEPTOR DE ESTROGENO ERß
US9623021B2 (en) *	2007-01-22	2017-04-18	Gtx, Inc.	Nuclear receptor binding agents
KR101763674B1 (ko)	2007-01-22	2017-08-01	지티엑스, 인코포레이티드	핵 수용체에 결합하는 물질
US9604931B2 (en)	2007-01-22	2017-03-28	Gtx, Inc.	Nuclear receptor binding agents
US20150018398A1 (en) *	2013-07-15	2015-01-15	The Regents Of The University Of California	Methods of using estrogen receptor-beta ligands as radiation mitigators
JP7376593B2 (ja) *	2018-12-31	2023-11-08	インテル・コーポレーション	人工知能を利用した安全保障システム

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5496828A (en) *	1994-08-22	1996-03-05	Eli Lilly And Company	Methods of inhibiting ulcerative mucositis
CA2248013A1 (en) *	1996-03-11	1997-09-18	Eli Lilly And Company	Methods of treating or preventing interstitial cystitis
NZ534348A (en) *	2000-01-28	2006-06-30	Endorech Inc	Selective estrogen receptor modulators in combination with estrogens
DK1343492T3 (da) *	2000-11-22	2006-03-06	Rxkinetix Inc	Behandling af mucositis
US7547433B2 (en) *	2001-02-15	2009-06-16	Access Pharmaceuticals, Inc.	Liquid formulations for the prevention and treatment of mucosal diseases and disorders
UA83620C2 (ru) *	2001-12-05	2008-08-11	Уайт	Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200301107A (en) *	2001-12-13	2003-07-01	Wyeth Corp	Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
TWI306450B (en) *	2001-12-13	2009-02-21	Wyeth Corp	Substituted phenyl naphthalenes as estrogenic agents
US20030220377A1 (en) *	2002-05-08	2003-11-27	Richard Chesworth	Indole compounds and their use as estrogen agonists/antagonists
CL2004000985A1 (es) *	2003-05-16	2005-01-14	Wyeth Corp	Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc

2006
- 2006-02-14 BR BRPI0608154A patent/BRPI0608154A2/pt not_active IP Right Cessation
- 2006-02-14 JP JP2007556226A patent/JP2008530210A/ja active Pending
- 2006-02-14 AU AU2006214515A patent/AU2006214515A1/en not_active Abandoned
- 2006-02-14 MX MX2007009914A patent/MX2007009914A/es unknown
- 2006-02-14 EP EP06734914A patent/EP1848427A1/en not_active Withdrawn
- 2006-02-14 US US11/353,611 patent/US20060211672A1/en not_active Abandoned
- 2006-02-14 RU RU2007128819/14A patent/RU2007128819A/ru unknown
- 2006-02-14 KR KR1020077018755A patent/KR20070103456A/ko not_active Withdrawn
- 2006-02-14 TW TW095104866A patent/TW200640451A/zh unknown
- 2006-02-14 CN CNA2006800049774A patent/CN101119721A/zh active Pending
- 2006-02-14 AR ARP060100515A patent/AR053332A1/es not_active Application Discontinuation
- 2006-02-14 WO PCT/US2006/005000 patent/WO2006088784A1/en not_active Ceased
- 2006-02-14 PE PE2006000172A patent/PE20061092A1/es not_active Application Discontinuation
- 2006-02-14 CA CA002596984A patent/CA2596984A1/en not_active Abandoned
- 2006-02-14 GT GT200600064A patent/GT200600064A/es unknown
2007
- 2007-07-20 CR CR9263A patent/CR9263A/es not_active Application Discontinuation
- 2007-07-25 NO NO20073901A patent/NO20073901L/no not_active Application Discontinuation
- 2007-07-25 NI NI200700182A patent/NI200700182A/es unknown
- 2007-08-02 IL IL185009A patent/IL185009A0/en unknown
- 2007-08-15 ZA ZA200706785A patent/ZA200706785B/xx unknown

Also Published As

Publication number	Publication date
GT200600064A (es)	2006-11-09
JP2008530210A (ja)	2008-08-07
AR053332A1 (es)	2007-05-02
PE20061092A1 (es)	2006-12-05
ZA200706785B (en)	2009-08-26
BRPI0608154A2 (pt)	2016-10-11
MX2007009914A (es)	2007-09-25
RU2007128819A (ru)	2009-03-27
CN101119721A (zh)	2008-02-06
NO20073901L (no)	2007-11-15
IL185009A0 (en)	2008-08-07
NI200700182A (es)	2008-05-13
WO2006088784A1 (en)	2006-08-24
CA2596984A1 (en)	2006-08-24
US20060211672A1 (en)	2006-09-21
EP1848427A1 (en)	2007-10-31
AU2006214515A1 (en)	2006-08-24
KR20070103456A (ko)	2007-10-23
CR9263A (es)	2007-11-23

Publication	Publication Date	Title
NO20170633A1 (no)	2008-02-07	Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
CY1107906T1 (el)	2013-09-04	Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
MX2021005764A (es)	2021-10-01	Composición farmacéutica que comprende inhibidores de poli (adenosina difosfato (adp)-ribosa) polimerasas (parp).
TW200600087A (en)	2006-01-01	Methods and compositions for treating amyloid-related diseases
MXPA05014166A (es)	2006-03-13	Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
TW200642694A (en)	2006-12-16	Anti-M-CSF antibody compositions
BRPI0508540B8 (pt)	2021-05-25	composto, composição farmacêutica, e, uso de um composto
WO2005025410A3 (en)	2005-12-22	Formulations and methods for treating breast cancer with morinda citrifolia and methylsulfonymethane
WO2008112164A3 (en)	2008-11-13	Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CR8766A (es)	2007-08-28	Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CL2007003557A1 (es)	2008-08-01	Compuestos derivados de heterociclos de nitrogeno, inhibidores de la actividad sobre b-raf; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
ECSP078057A (es)	2008-01-23	Formulaciones de estrógenos conjugados y bazedoxifeno
MX2008015775A (es)	2009-04-17	Compuestos y composiciones para tratamiento de cancer.
MX2008002492A (es)	2008-04-03	Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
TW200642684A (en)	2006-12-16	Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and taxanes
TW200731991A (en)	2007-09-01	Lipophilic di(anticancer drug) compounds, compositions and related methods
EP1503748A4 (en)	2009-10-21	DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
TW200640451A (en)	2006-12-01	Use of estrogen receptor-β selective agonists for radiation- or chemotherapy-induced mucositis and radiation cystitis
TNSN07453A1 (en)	2009-03-17	Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
MX2012012479A (es)	2013-07-03	Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.
BRPI0511475A (pt)	2007-12-26	combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
BRPI0516464A (pt)	2008-09-09	formulação farmacêutica, método para a preparação de um produto farmacêutico, e, uso de uma formulação farmacêutica
AR048672A1 (es)	2006-05-17	Tabletas de desintegracion que comprenden licarbazepina
DK1523985T3 (da)	2010-05-31	Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
BRPI0614810A2 (pt)	2009-08-04	combinação de compostos orgánicos